Ticagrelore Alone Post PCI
ConditionCoronary Artery Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age20-80
SponsorShiraz University of Medical Sciences
About this trial
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic
Eligibility criteria
Qualifiers
Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome
The patient has provided written informed consent as approved by the ethics committee of the Shiraz University of Medical Sciences.
Disqualifiers
Contraindication to aspirin, clopidogrel, ticagrelor, or any other reason that study drug should not be administered (including hypersensitivity, moderate or severe liver disease, active bleeding, and major surgery within 30 days)
Atrial fibrillation or other indication for oral anticoagulant therapy.
Concomitant oral or IV therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices (cyclosporine, and quinidine), or strong CYP3A inducers ( rifampin, rifampicin, phenytoin, and carbamazepine)
Females of child-bearing age unless negative pregnancy test at screening and willing to use effective contraception for the duration of trial
Trial design
Treatments tested in this trial
- aspirin 80 mg and clopidogrel 75 mg daily
- Ticagrelor 90 MG
Treatment groups
5,400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov